Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

OUTLINE: This is a multi-center study. * Cisplatin 50 mg/m2 d1, 8, 29, 36 * Etoposide 50 mg/m2/day d1-5, 29-33 * Radiation 5940 cGy (180 cGy/day) Patients with CR, PR, SD Randomized to either:Docetaxel75 mg/m2 q3wk X 3 cycles or Observation Only Performance Status: ECOG 0 or 1 Life Expectancy: Not specified Hematopoietic: * ANC \> 1,500/mm3 * Platelet count \> 100,000/mm3 * Hemoglobin \> 8 g/dl. PRBC transfusions will be allowed to increase hemoglobin to \>8 g/dl Hepatic: * Serum bilirubin \< institutional upper limit of normal (ULN) * AST \< 2.5 X the upper limits of normal if alkaline phosphatase is \< ULN, or alkaline phosphatase may be up to 4 X ULN if AST are \< ULN Renal: * Serum creatinine of \< 2 mg/dl or calculated creatinine clearance \> 50 cc/min Cardiovascular: * No clinically significant history of cardiac disease, (i.e. uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past year, or cardiac ventricular arrhythmias requiring medication). Pulmonary: * Pre-registration FEV1 \> 1 liters by spirometry within 42 days prior to study treatment.